We are initiating coverage on Pluristem Therapeutics, a company developing allogenic cell therapies derived from donated placental tissue. The company has two products, PLX-PAD for the treatment of vascular disorders and PLX-R18 for hematologic disorders. The lead program is for critical limb ischemia (CLI), with a Phase III expected to start in 2017. Based on feedback from both the FDA and EMA, a single pivotal 250-patient study will be required for approval. Our valuation is $182m.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First product to enter market
- Published:
23 Nov 2016 -
Author:
Dr Nathaniel Calloway -
Pages:
16
We are initiating coverage on Pluristem Therapeutics, a company developing allogenic cell therapies derived from donated placental tissue. The company has two products, PLX-PAD for the treatment of vascular disorders and PLX-R18 for hematologic disorders. The lead program is for critical limb ischemia (CLI), with a Phase III expected to start in 2017. Based on feedback from both the FDA and EMA, a single pivotal 250-patient study will be required for approval. Our valuation is $182m.